What is the Szent-Györgyi Prize?
The Szent-Györgyi Prize for Progress in Cancer Research was established in honor of NFCR’s co-founder, Albert Szent-Györgyi, M.D., Ph.D., who received the 1937 Nobel Prize for his study of vitamin C and cell respiration. The prize is a symbol of NFCR’s enduring commitment to uphold Dr. Szent-Györgyi’s vision of curing cancer through innovation and collaboration.
The annual prize honors scientists who have made an original discovery or breakthrough in scientific understanding that has had a lasting impact on the cancer field and a direct impact of saving people’s lives. In addition to winning the coveted award itself, prize recipients are given a $25,000 honorarium and attend a gala in their honor. The award serves to highlight the essential role basic research plays in understanding cancer.
Nominations for the Prize may be made by individuals from the research community, industry, government, or other organizations who are sufficiently familiar with the research accomplishments and contributions of the nominee. Self-nominations are not accepted. Candidates must have made an original discovery or breakthrough in scientific understanding that has led to better prevention, earlier diagnosis, or new treatments for patients with cancer.
The Szent-Györgyi Prize Selection Committee has been established to advise and consult with the National Foundation for Cancer Research on each year’s pool of Prize nominees.
The Prize Winner each year will serve as the selection chair of the Szent-Györgyi Prize Selection Committee for the following year.
2019 Award Recipient
Steven A. Rosenberg, M.D., Ph.D
2019 Szent-Györgyi Prize for Progress in Cancer Research has been awarded to Steven A. Rosenberg, M.D., Ph.D for pioneering and revolutionizing the field now known as cancer immunotherapy. He has remained at its forefront for over four decades while Chief of the NCI Center for Cancer Research’s surgery branch in Bethesda, Maryland. His basic, translational and applied research efforts have contributed immeasurably to groundbreaking advances in therapy and the later development of multiple drugs, including the first ever cancer immunotherapy approved by the U.S. Food and Drug Administration.
“The impact of Dr. Rosenberg’s discoveries and pioneering work is phenomenal for cancer patients and for the research community,” expressed Sujuan Ba, Ph.D., co-chair of the 2019 Prize selection committee and president and CEO of NFCR. “His accomplishments in immunotherapy are the embodiment of what NFCR’s Szent-Györgyi Prize entails and he richly deserves this prestigious honor.”
2020 Szent-Györgyi Prize Ceremony
Saturday, April 25th, 2020